Abstract
‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Current Pharmaceutical Design
Title: Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Volume: 17 Issue: 12
Author(s): Paula J. Edge and Mark S. Gold
Affiliation:
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Abstract: ‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Export Options
About this article
Cite this article as:
J. Edge Paula and S. Gold Mark, Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656738
DOI https://dx.doi.org/10.2174/138161211795656738 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Post-cardiac Arrest Syndrome in Children
Current Pediatric Reviews Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Exploration of Different Methodologies for Synthesizing Biologically Important Benzothiazoles: An Overview
Current Organic Synthesis Comparative Effect of Telmisartan vs Lisinopril on Blood Pressure in Patients of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Current Topics in Medicinal Chemistry High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials
Current Cardiology Reviews Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review of Dietary Influences on Cardiovascular Health: Part 1: the role of Dietary Nutrients
Cardiovascular & Hematological Disorders-Drug Targets Atrial Conduction Disorders
Current Cardiology Reviews Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding
Current Cardiology Reviews Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews